About ARTIDIS

ARTIDIS's nanomechanical sensor captures the physical properties of tissue enabling the clinician to differentiate between benign and malignant tissue in under three hours. In addition, the technology allows the clinician to define the aggressiveness of the tumor with very high accuracy based on the nanomechanical signature of the cells. Only very soft cells can squeeze through all different tissues to create distant metastases that are responsible for more than 90% of cancer related deaths. Th

Company Highlights
Year Founded

2018

icon-altEmployees

68

Location (HQ)

CHE

Since Last Funding

1 year 3 months

Monthly Website Visitors

2.4K

icon-altTotal Investment Amt

$42M

Last Funding Round

Series A

icon-altYoY Headcount Growth

9.66%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Medical Device

Medical Equipment Manufacturing

Fitness